$1.36
+0.00 (+0.00%)
Open$1.40
Previous Close$1.36
Day High$1.46
Day Low$1.35
52W High$9.50
52W Low$1.28
Volume—
Avg Volume71.0K
Market Cap48.61M
P/E Ratio—
EPS$-10.60
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+1,523.5% upside
Current
$1.36
$1.36
Target
$22.08
$22.08
$13.69
$22.08 avg
$22.84
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 12.10M | 11.96M | 10.98M |
| Net Income | 3.15M | 2.42M | 2.50M |
| Profit Margin | 26.0% | 20.2% | 22.8% |
| EBITDA | 4.53M | 4.37M | 3.74M |
| Free Cash Flow | 1.56M | 1.43M | 1.67M |
| Rev Growth | +0.7% | +19.7% | +24.9% |
| Debt/Equity | 0.93 | 0.73 | 0.93 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |